Kenvue Inc. (NYSE:KVUE) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. cut its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 35.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,527,592 shares of the company’s stock after selling 835,667 shares during the quarter. Russell Investments Group Ltd. owned about 0.08% of Kenvue worth $32,614,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Kenvue by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company’s stock worth $4,665,908,000 after purchasing an additional 1,636,741 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Kenvue by 12.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company’s stock valued at $2,085,070,000 after buying an additional 10,682,003 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Kenvue by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company’s stock worth $980,989,000 after acquiring an additional 1,391,854 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Kenvue by 61.5% during the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company’s stock worth $912,059,000 after acquiring an additional 16,269,721 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Kenvue by 2.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 24,972,777 shares of the company’s stock valued at $533,169,000 after acquiring an additional 561,570 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Down 2.6 %

Shares of KVUE opened at $21.76 on Tuesday. The company’s 50-day simple moving average is $22.60 and its 200-day simple moving average is $22.45. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The stock has a market capitalization of $41.58 billion, a PE ratio of 41.05, a P/E/G ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.77%. Kenvue’s payout ratio is 154.72%.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Piper Sandler lifted their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research note on Monday, February 24th. Canaccord Genuity Group lifted their price target on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Evercore ISI started coverage on Kenvue in a research report on Monday, March 24th. They issued an “in-line” rating and a $25.00 price objective for the company. UBS Group reduced their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Finally, Citigroup lowered their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $24.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.